Compare Incyte Corporation (INCY) vs PayPal Holdings, Inc. (PYPL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs PayPal Holdings, Inc. — how do they compare? Incyte Corporation trades at $121.25 (market cap $24.54B), while PayPal Holdings, Inc. trades at $58.44 (market cap $50.47B). The key difference: PayPal Holdings, Inc. is far larger — about 2.1× Incyte Corporation's market cap, and PayPal Holdings, Inc. pays a 0.95% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | PYPL | |
|---|---|---|
Market Cap | $24.54B | $50.47B |
Sector | Health | Financials |
52-Week High | $129.93 | $76.13 |
52-Week Low | $81.61 | $39.08 |
Enterprise Value | $20.04B | $52.62B |
Dividend Yield | — | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
PayPal trades at $59.07, showing stability with no recent price change. The stock exhibits bullish technical signals with strong moving average support and trades near key resistance at $60. Fundamentally, PayPal delivered Q2 2026 earnings beat with $1.38 EPS versus $1.28 expected, while revenue grew to $33.17 billion in 2025 with improving profit margins. Recent news highlights acquisition interest and strategic partnerships expanding payment capabilities.
PayPal presents a compelling value opportunity with attractive valuation multiples (P/E 11.15, P/S 1.6) and strong cash flow generation ($6.42B operating cash flow). However, risks include competitive pressures in digital payments and execution challenges under new leadership. Analyst consensus leans neutral with 60% hold ratings, though the $58.75 price target suggests limited upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About PayPal Holdings, Inc.
PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →
